torvutatug samrotecan

An antibody-drug conjugate (ADC) composed of torvutatug, a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated to samrotecan, a linker conjugated to exatecan, with potential antineoplastic activity. Upon administration of torvutatug samrotecan, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon binding, cellular uptake and linker cleavage, exatecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and generating DNA single- and double-strand breaks, and leading to cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of FRa-expressing tumor cells. FRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.